Clinical Indications

clinicalindications

The Dilon Molecular Breast Imaging (MBI) Procedure can detect cancers missed by mammography and ultrasound, while leading to fewer benign biopsies than MRI. According to clinical studies, MBI has very high sensitivity for identifying earlier stage cancers as small as 1 mm.

Clinical Indications proposed in the Medical Literature*

In diagnostic breast patients with an unresolved diagnostic dilemma and:

  • Equivocal exams
  • Dense-breast with indeterminate breast abnormalities
  • Breast implants
  • Discordant findings
  • As an alternate to MRI in patients who can not have an MRI study

In cancer patients to:

  • Monitor for recurrence
  • Evaluate the extent of disease (initial staging)
  • Detect multi-centric, multi-focal, or bilateral disease
  • Assess response to neoadjuvant chemotherapy
  • As an adjunct to a limited mammogram
  • Surgical planning for residual disease
  • As an alternate to MRI for patients who can not have an MRI study

*Goldsmith et alSNM Practice Guideline for Breast Scintigraphywith Breast-Specific Gamma-Cameras 1.0

What can MBI do?

For the breast radiologist

  • Find cancers missed by mammography and ultrasound, especially in difficult and dense breast cases, while leading to fewer benign biopsies than MRI
  • Provide a high negative predictive value to eliminate questionable findings on mammography and ultrasound

For the breast surgeon

  • Improve surgical planning by finding additional disease
  • Provide a better understanding of the position of the tumor to help in planning surgery
  • Monitor tumor response to chemotherapy